ReviewThe Journal of hand surgery, European volume2023
Treatments for early-stage Dupuytren's disease: an evidence-based approach.
Review in The Journal of hand surgery, European volume, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- The Cost-Effectiveness of Collagenase Injection Versus Limited Fasciectomy for Moderate Dupuytren's Contracture: An Economic Evaluation of the Dupuytren's Interventions Surgery Versus Collagenase Trial and a Decision Analytical Model.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026Trial
- Quality of Life and Toxicities Following Whole-Palm Versus Involved-Field Radiation Therapy for Dupuytren's Disease: A Substudy From a Randomized Trial.Advances in radiation oncology · 2026Article
- Angiotensin Receptor Blockers Are Not Associated With Protective Benefits in Dupuytren's Disease.Hand (New York, N.Y.) · 2026Article
- Uncoupling TGFβ1 signalling from collagen protein synthesis in Dupuytren's disease.The Journal of pathology · 2026Article
- Development of a 3D In Vitro Model of Dupuytren's Disease as a Platform for Drug Screening.Cellular and molecular bioengineering · 2026Article
- Psychometric Evaluation of the Serbian Version of the Southampton Dupuytren's Scoring Scheme in Patients with Dupuytren's Contracture.Journal of clinical medicine · 2025Article
- Pathological Changes in Extracellular Matrix Composition Orchestrate the Fibrotic Feedback Loop Through Macrophage Activation in Dupuytren's Contracture.International journal of molecular sciences · 2025Article
- Challenges and innovations in the surgical treatment of advanced Dupuytren disease by percutaneous needle fasciotomy: indications, limitations, and medico-legal implications.Journal of orthopaedic surgery and research · 2024Article
- Pre-operative hand therapy management of Dupuytren's disease: A systematic review.Hand therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current treatments for Dupuytren's disease are limited to late-stage disease when patients have developed flexion contractures and have impaired hand function. They all have limitations, including the risk of recurrence and complications. The use of treatments for early-stage disease, such as intralesional steroid injections or radiotherapy which lack a clear biological basis or evidence of effectiveness based robust randomized, double blind, placebo-controlled trials, highlights the desire of patients to access treatments before they develop significant flexion contractures. A detailed understanding of the cellular landscape and molecular signalling in nodules of early-stage disease would permit the identification of potential therapeutic targets. This approach led to the identification of tumour necrosis factor (TNF) as a target. A phase 2a clinical trial identified 40 mg in 0.4 mL adalimumab as the most efficacious dose and a subsequent randomized, double blind, placebo-controlled phase 2b trial showed that four intranodular injections at 3-month intervals resulted in decrease in nodule hardness and size on ultrasound scan at 12 months, and both parameters continued to decrease further at 18 months, 9 months after the final injection. This type of approach provides clinicians with a robust evidence base for advising their patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.